79 related articles for article (PubMed ID: 22808577)
1. A case report: successful treatment of meningeal metastasis with concurrent whole brain radiotherapy and erlotinib in a patient with non-small cell lung cancer.
Huang J; Dong XR; Lu HD; Liu L
West Indian Med J; 2012 Jan; 61(1):106-8. PubMed ID: 22808577
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes in extracranial tumor sites and unusual toxicities with concurrent whole brain radiation (WBRT) and Erlotinib treatment in patients with non-small cell lung cancer (NSCLC) with brain metastasis.
Olmez I; Donahue BR; Butler JS; Huang Y; Rubin P; Xu Y
Lung Cancer; 2010 Nov; 70(2):174-9. PubMed ID: 20207442
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non-small-cell lung cancer.
Lind JS; Lagerwaard FJ; Smit EF; Senan S
Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1391-6. PubMed ID: 19289264
[TBL] [Abstract][Full Text] [Related]
4. Recurrent responses to non-small cell lung cancer brain metastases with erlotinib.
Popat S; Hughes S; Papadopoulos P; Wilkins A; Moore S; Priest K; Meehan L; Norton A; O'Brien M
Lung Cancer; 2007 Apr; 56(1):135-7. PubMed ID: 17157952
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI.
Yi HG; Kim HJ; Kim YJ; Han SW; Oh DY; Lee SH; Kim DW; Im SA; Kim TY; Kim CS; Heo DS; Bang YJ
Lung Cancer; 2009 Jul; 65(1):80-4. PubMed ID: 19059670
[TBL] [Abstract][Full Text] [Related]
6. [Erlotinib and nonsmall cell lung cancer with brain metastases: a case study with a complete and prolonged response over 17 months].
Mairovitz A; Staub E; Le Floch H; Rivière F; Bonnichon A; Margery J; Vaylet F
Rev Pneumol Clin; 2009 Oct; 65(5):318-21. PubMed ID: 19878809
[TBL] [Abstract][Full Text] [Related]
7. CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation.
Pan M; Santamaria M; Wollman DB
Nat Clin Pract Oncol; 2007 Oct; 4(10):603-7. PubMed ID: 17898810
[TBL] [Abstract][Full Text] [Related]
8. Carcinomatous meningitis in non-small-cell lung cancer: response to high-dose erlotinib.
Dhruva N; Socinski MA
J Clin Oncol; 2009 Aug; 27(22):e31-2. PubMed ID: 19487379
[No Abstract] [Full Text] [Related]
9. Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: a case report and review of the literature.
Togashi Y; Masago K; Hamatani Y; Sakamori Y; Nagai H; Kim YH; Mishima M
Lung Cancer; 2012 Aug; 77(2):464-8. PubMed ID: 22579408
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC): analysis of the Australian subpopulation of the TRUST study.
Boyer M; Horwood K; Pavlakis N; De Souza P; Millward M; Stein B; Johnston M; Abell F; Rischin D
Asia Pac J Clin Oncol; 2012 Sep; 8(3):248-54. PubMed ID: 22898114
[TBL] [Abstract][Full Text] [Related]
11. The effectiveness of erlotinib against brain metastases in non-small cell lung cancer patients.
Bai H; Han B
Am J Clin Oncol; 2013 Apr; 36(2):110-5. PubMed ID: 22391431
[TBL] [Abstract][Full Text] [Related]
12. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
Herbst RS; Prager D; Hermann R; Fehrenbacher L; Johnson BE; Sandler A; Kris MG; Tran HT; Klein P; Li X; Ramies D; Johnson DH; Miller VA;
J Clin Oncol; 2005 Sep; 23(25):5892-9. PubMed ID: 16043829
[TBL] [Abstract][Full Text] [Related]
13. Unusual tumor response and toxicity from radiation and concurrent erlotinib for non-small-cell lung cancer.
Nanda A; Dias-Santagata DC; Stubbs H; O'Hara CJ; Zaner KS; Lynch TJ; Willers H
Clin Lung Cancer; 2008 Sep; 9(5):285-7. PubMed ID: 18824451
[TBL] [Abstract][Full Text] [Related]
14. Fatal interstitial lung disease after erlotinib administration in a patient with radiation fibrosis.
Um SJ; Lee SK; Yang DK; Son C; Roh MS; Kim KN; Lee KN; Choi PJ
Clin Respir J; 2009 Jul; 3(3):181-4. PubMed ID: 20298401
[TBL] [Abstract][Full Text] [Related]
15. Modern treatment of lung cancer: case 2. Response to erlotinib after failure of gefitinib in a patient with advanced non-small-cell lung carcinoma.
Garfield DH
J Clin Oncol; 2005 Oct; 23(30):7738-40. PubMed ID: 16234533
[No Abstract] [Full Text] [Related]
16. Effects of erlotinib first-line maintenance therapy versus placebo on the health-related quality of life of patients with metastatic non-small-cell lung cancer.
Juhász E; Kim JH; Klingelschmitt G; Walzer S
Eur J Cancer; 2013 Apr; 49(6):1205-15. PubMed ID: 23477998
[TBL] [Abstract][Full Text] [Related]
17. Erlotinib treatment for persistent spontaneous pneumothorax in non-small cell lung cancer: a case report.
Ren SX; Zhou SW; Zhang L; Zhou CC
Chin Med J (Engl); 2010 Dec; 123(23):3501-3. PubMed ID: 22166539
[No Abstract] [Full Text] [Related]
18. Afatinib for Erlotinib Refractory Brain Metastases in a Patient with EGFR-Mutant Non-Small-Cell Lung Cancer: Can High-Affinity TKI Substitute for High-Dose TKI?
Hata A; Katakami N
J Thorac Oncol; 2015 Jul; 10(7):e65-6. PubMed ID: 26134239
[No Abstract] [Full Text] [Related]
19. [Whole-brain radiotherapy combined with COAPC regimen in patients with non-small cell lung cancer].
Chen LK; Xu GC; Liu GZ; Liang Y; Liu JL; Zhou XM
Ai Zheng; 2003 Apr; 22(4):407-10. PubMed ID: 12704000
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of erlotinib as third-line monotherapy in patients with advanced non-small-cell lung cancer without epidermal growth factor receptor mutations.
Matsuura S; Inui N; Ozawa Y; Nakamura Y; Toyoshima M; Yasuda K; Yamada T; Shirai T; Suganuma H; Yokomura K; Suda T; Chida K
Jpn J Clin Oncol; 2011 Aug; 41(8):959-63. PubMed ID: 21715361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]